Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Usana Health SciencesUSNA -3.96%66 3-Year EBITDA Growth Rate is -13.10% as of Jun. 2026. GuruFocus rates USNA with a GF Score™ of 66/100 and a GF Value™ of $35.64 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,665 Consumer Packaged Goods companies, Usana Health Sciences ranks worse than 83.84% on this metric.
During the past 12 months, Usana Health Sciences's average EBITDA Per Share Growth Rate was -75.50% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was -13.10% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -15.00% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was -1.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Usana Health Sciences was 97.40% per year. The lowest was -18.40% per year. And the median was 10.30% per year.
Usana Health Sciences (NYSE:USNA) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Usana Health Sciences 3-Year EBITDA Growth Rate Related Terms
USNA vs NATR, BYND, BGS: 3-Year EBITDA Growth Rate Comparison
For the Packaged Foods subindustry, Usana Health Sciences's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Usana Health Sciences 3-Year EBITDA Growth Rate vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Usana Health Sciences's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Usana Health Sciences's 3-Year EBITDA Growth Rate falls into.
Usana Health Sciences 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of -13.10% mean?
Usana Health Sciences (USNA) has a 3-Year EBITDA Growth Rate of -13.10% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Usana Health Sciences and its competitors. According to the industry distribution chart, Usana Health Sciences ranks #1396 out of 1665 companies in the Consumer Packaged Goods industry, placing it in the top 83.8%.
Is Usana Health Sciences' 3-Year EBITDA Growth Rate too high?
Usana Health Sciences' current 3-Year EBITDA Growth Rate is -13.10%. Based on the distribution chart, Usana Health Sciences ranks #1396 out of 1665 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Usana Health Sciences has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Usana Health Sciences' 3-Year EBITDA Growth Rate compare to NATR and BYND?
According to the Consumer Packaged Goods industry distribution chart, Usana Health Sciences ranks #1396 out of 1665 companies for 3-Year EBITDA Growth Rate. This places Usana Health Sciences in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Consumer Packaged Goods company?
The median 3-Year EBITDA Growth Rate among Consumer Packaged Goods companies is 8.20, based on 1,665 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Usana Health Sciences and its competitors. For the Consumer Packaged Goods industry, the median 3-Year EBITDA Growth Rate is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Usana Health Sciences's current 3-Year EBITDA Growth Rate is -13.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Usana Health Sciences stock overvalued right now?
Based on GuruFocus' analysis, Usana Health Sciences (USNA) is currently considered Possible Value Trap. The stock's GF Value™ is $35.64, compared to a current price of $13.70 — trading 61.6% below its estimated fair value. The current 3-Year EBITDA Growth Rate is -13.10%. Usana Health Sciences' overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Usana Health Sciences (USNA), the current 3-Year EBITDA Growth Rate is -13.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Usana Health Sciences (USNA) Overvalued in 2026?
Based on GuruFocus' analysis, Usana Health Sciences stock appears to be undervalued.
The current stock price of $13.70 is trading 61.6% below its estimated GF Value™ of $35.64.
GuruFocus considers Usana Health Sciences to be Possible Value Trap.
Key valuation signals for USNA:
3-Year EBITDA Growth Rate: -13.10%
GF Value™: $35.64 vs. price of $13.70 (61.6% below fair value)
No single metric tells the full story. See the USNA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Usana Health Sciences Inc develops and manufactures high-quality nutritional supplements, functional foods, and personal care products that are sold throughout the world. The company has developed and manufactured high-quality, science-based nutritional, personal care, and skincare products with a primary focus on promoting long-term health and wellness. The Company's reporting units for goodwill purposes are tied to its reportable segments: Core nutritional and Hiya direct-to-consumer. The core nutritional segment consists of three individual reporting units that are determined based on the operational nature of the business: Buy-Sell, China, and India. Geographically, it is in Asia Pacific, the Americas, and Europe. With the majority of revenue from Asia Pacific(Greater China).
66GF Score
Get the complete analysis for USNA
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
USNA has been successfully added to your 
